FindTrial
Sign In

Bimatoprost SR

DRUG10 trials

Sponsors

Abbvie Deutschland GmbH & Co. KG, AbbVie Deutschland GmbH & Co. KG, Allergan, AbbVie, Allergan Limited

Conditions

GlaucomaGlaucoma, Open-AngleOcular HypertensionOcular hypertensionOpen-Angle GlaucomaOpen-Angle Ocular HypertensionOpen-angle GlaucomaOpen-angle glaucoma

Phase 3

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
CompletedNCT02247804
AllerganGlaucoma, Open-Angle, Ocular Hypertension
Start: 2014-12-15End: 2019-07-19Updated: 2020-06-11
Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension
CompletedNCT02250651
AllerganGlaucoma, Open-Angle, Ocular Hypertension
Start: 2014-12-15End: 2020-07-22Updated: 2021-07-28
Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension
CompletedNCT02507687
AbbVieGlaucoma, Open-Angle, Ocular Hypertension
Start: 2015-08-27End: 2023-05-31Updated: 2024-05-10
A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension
CompletedNCT02636946
AllerganGlaucoma, Open-Angle Ocular Hypertension
Start: 2016-02-24End: 2021-01-26Updated: 2022-02-23
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension
NL-OMON45083
Allergan Limitedglaucoma and increased pressure inside the eye
Target: 5Updated: 2024-02-28
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
Active, not recruitingNCT03891446
AbbVieOcular Hypertension, Open-Angle Glaucoma
Start: 2019-03-27End: 2026-08-31Updated: 2025-08-28
A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
CompletedNCT04285580
AbbVieOcular Hypertension, Open-Angle Glaucoma
Start: 2020-06-11End: 2022-05-14Updated: 2023-06-08
A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension
CompletedCTIS2022-502380-37-00
Abbvie Deutschland GmbH & Co. KGOcular Hypertension, Open-Angle Glaucoma
Start: 2019-08-02End: 2025-07-11Target: 167Updated: 2025-05-28
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension
CompletedCTIS2023-504601-36-00
AbbVie Deutschland GmbH & Co. KGOcular Hypertension, Open-angle Glaucoma
Start: 2019-11-20End: 2025-04-10Target: 28Updated: 2025-04-15
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension
Active, not recruitingCTIS2024-519595-87-00
AbbVie Deutschland GmbH & Co. KGOcular hypertension, Open-angle glaucoma
Start: 2015-12-15Target: 3Updated: 2025-06-04

Related Papers

Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty.
2025-01-103 citations
Single Administration of Bimatoprost Implant: Effects on 24-Hour Intraocular Pressure and 1-Year Outcomes.
2023-06-1912 citations
Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
Journal of Ocular Pharmacology and Therapeutics2022-11-1526 citations
Single Administration of Intracameral Bimatoprost Implant 10 µg in Patients with Open-Angle Glaucoma or Ocular Hypertension
Ophthalmology and Therapy2022-05-2827 citations
Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)
Drugs2021-11-0162 citations
24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Drugs2019-12-2896 citations